|
At
the helm of sunrise
Besides generating trained manpower and a knowledge base in
biotechnology, India is proving to be an ideal setting for
manufacturing activities and high-level biotechnology research
programmes. With government initiatives, Indian biotechnology
is poised for tremendous growth. By Sapna Dogra
'Portfolio
management will take care of the Patent Act'
Nicholas Hall, the man behind UK based Nicholas Hall &
Company, specialists in targeted OTC branding and market analysis.
With it reach in several international markets and many years
of experience Hall can provide OTC branding advice specific
to the market you operate in. Nandini Patwardhan catches up
with him to explore various aspects of OTC marketing, his
company and his plans for India.
Stock
Watch
IRL
ties up with UK based Synexus
The research wing of Institute of Clinical Research (ICRI),
ICRI Research Limited (IRL), has entered into a strategic
alliance with Synexus Clinical Research. Synexus Clinical
Research is a UK-based patient recruitment organisation in
Europe which undertakes clinical trials for pharmaceutical
companies and CROs.
Lupin
gets USFDA nod for Cephalexin capsules
Lupin has received USFDA approval for its ANDA for Cephalexin
capsules USP 250 mg and 500 mg. The US market for Cephalexin
capsules is estimated at $80 million.
Zydus
Cadila gets approval for Sertraline from AFSSAPS
Zydus Cadila has received approval from the AFSSAPS, the French
regulatory agency to market Sertraline capsules 25 mg and
50 mg. The drug falls into the CNS segment in the French market.
Indian
pharma throws an eastward glance
Indian pharma industry is going places and its high time it
makes an inroad into Japan, the Asian pharma giant. The Indo-Japanese
conference will mark the beginning of a new partnership in
drug discovery, Katya Naidu reports.
Indian
Pharmaceutical Congress: Too full a plate
One of India's largest pharma events, the IPC, assembled in
Hyderabad this fortnight. Deepali Gupta presents some of the
key highlights.
|
